Overview

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Status:
Recruiting
Trial end date:
2024-04-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the antiviral activity of JNJ-64281802 versus placebo in terms of reduction of dengue virus 1 (DENV-1) ribonucleic acid (RNA) viral load (VL).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC